Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Accounts Payables (2020 - 2025)

IceCure Medical (ICCM) has disclosed Accounts Payables for 5 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Accounts Payables rose 145.42% to $1.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.2 million, a 145.42% increase, with the full-year FY2024 number at $1.2 million, up 145.42% from a year prior.
  • Accounts Payables was $1.2 million for Q4 2024 at IceCure Medical, up from $502000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.2 million in Q4 2024 to a low of $502000.0 in Q4 2023.
  • A 5-year average of $794800.0 and a median of $714000.0 in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: decreased 29.69% in 2023, then skyrocketed 145.42% in 2024.
  • IceCure Medical's Accounts Payables stood at $645000.0 in 2020, then soared by 36.59% to $881000.0 in 2021, then fell by 18.96% to $714000.0 in 2022, then dropped by 29.69% to $502000.0 in 2023, then surged by 145.42% to $1.2 million in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Accounts Payables are $1.2 million (Q4 2024), $502000.0 (Q4 2023), and $714000.0 (Q4 2022).